Module 17 – The Regulatory Landscape
Part of the Purus Lumina Device Care Education Programme
The regulatory framework governs the prescription. It does not govern what happens to the device.
The United Kingdom has one of the most developed regulatory frameworks for Cannabis-Based Products for Medicinal use of any country in the world. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates the licensing and quality of CBPMs. The Home Office regulates their classification and supply under the Misuse of Drugs Act 1971. NHS England and NICE govern their clinical use and commissioning. The Care Quality Commission regulates the providers who prescribe them.
None of these bodies has issued guidance on how the device used to administer a CBPM should be maintained.
This is the regulatory landscape this module documents. Not what the regulators have said — but what they have not said, and why the absence of that guidance is itself a regulatory finding.
The MHRA
The Medicines and Healthcare products Regulatory Agency is the UK body responsible for ensuring that medicines and medical devices work and are acceptably safe. It regulates CBPMs as medicines and regulates dry herb devices — where they carry UKCA or CE marking as medical devices — as medical devices.
What the MHRA has said: The MHRA has issued guidance on the licensing of CBPMs, on the requirements for CBPM manufacturers, and on the classification of cannabis-based products. It has issued guidance on the regulation of medical devices, including the requirements for UKCA marking and post-market surveillance.
What the MHRA has not said: The MHRA has not issued guidance on the maintenance of medical devices used to administer CBPMs in a home setting. It has not issued guidance on the cleaning standard, the replacement schedule, or the storage conditions for these devices. It has not issued guidance on what constitutes off-label use of a CBPM delivery device in the context of a prescribed medicine. The gap between what the MHRA regulates and what it has documented for patients is the gap this curriculum exists to fill.
The submission: This curriculum has been submitted to the MHRA as a formal educational contribution to a documented gap in patient care. It is the first structured, published document to address device care standards for CBPM administration in the UK. The MHRA is invited to adopt, reference, or build upon it in any future guidance it issues on this subject.
The Home Office
The Home Office is responsible for the classification of controlled drugs under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001. Cannabis remains a Class B controlled substance. CBPMs are Schedule 2 controlled drugs — they can be prescribed by specialist clinicians but are subject to strict controls on production, supply, and possession.
What the Home Office has said: The Home Office has issued guidance on the legal framework for CBPM prescribing, on the requirements for Schedule 2 controlled drug handling, and on the obligations of patients who possess a prescribed CBPM. It has issued guidance on travelling with a CBPM prescription.
What the Home Office has not said: The Home Office has not issued guidance on the device through which a CBPM is administered. It has not addressed the question of whether a contaminated device that alters the dose of a Schedule 2 controlled drug constitutes a compliance issue under the controlled drug framework. It has not addressed the question of what standard of device maintenance is required to demonstrate responsible possession and use of a prescribed controlled substance.
The submission: This curriculum has been submitted to the Home Office as a formal educational contribution. The question of whether device maintenance is a relevant consideration under the controlled drug framework is one that the Home Office has the authority to address. This curriculum documents that the question exists and has not been answered.
NHS England and NICE
NHS England commissions healthcare services and sets the framework within which CBPMs are prescribed on the NHS. The National Institute for Health and Care Excellence (NICE) produces clinical guidelines that inform prescribing decisions across the NHS and the independent sector.
What NHS England has said: NHS England has issued commissioning guidance for CBPMs, including the conditions for which they may be prescribed and the specialist clinician requirements. It has not issued guidance on device care.
What NICE has said: NICE has produced technology appraisals and evidence reviews for specific CBPMs, including Epidyolex for treatment-resistant epilepsy and Sativex for MS spasticity. It has not produced guidance on the administration devices used to deliver inhaled CBPMs, and has not addressed device maintenance in any published guideline.
The gap in clinical guidelines: A NICE clinical guideline that addresses the prescribing of an inhaled CBPM without addressing the maintenance of the device through which it is inhaled is an incomplete guideline. The clinical outcome of the prescription is affected by the condition of the device. A guideline that does not address device condition is a guideline that does not fully address the clinical outcome it is designed to optimise. This curriculum submits that finding to NICE as a matter of public record.
The Care Quality Commission
The Care Quality Commission regulates health and social care providers in England, including the clinics operating within the prescribed CBPM pathway that prescribe the majority of CBPMs in the UK. CQC registration requires providers to meet fundamental standards of care, including the safe management of medicines.
What the CQC has said: The CQC's fundamental standards require registered providers to ensure that medicines are managed safely. This includes the prescribing, dispensing, and administration of medicines. It does not currently include specific guidance on the maintenance of devices used to administer prescribed medicines in a home setting.
The implication: A clinic operating within the prescribed CBPM pathway that prescribes a CBPM for home administration via a dry herb device, without providing the patient with a device care protocol, may not be meeting the CQC's fundamental standard for safe medicine management. The CQC has not tested this question. This curriculum documents that it should.
The UK Medical Devices Regulations 2002
The UK Medical Devices Regulations 2002 govern the placing on the market and putting into service of medical devices in the United Kingdom. A dry herb device that carries UKCA or CE marking as a medical device is subject to these regulations. The manufacturer is required to provide instructions for use that enable the device to be used safely and as intended.
The instructions for use gap: The instructions for use provided by manufacturers of dry herb devices used as CBPM delivery devices are written for general consumer use. They are not written for the clinical context of prescribed CBPM administration. They do not address the frequency of use typical of a patient prescribed a CBPM. They do not address the regulatory implications of non-compliance with the cleaning instructions. They do not address shared use, carer-assisted use, or paediatric use.
The regulatory question: Whether the instructions for use provided by manufacturers of dry herb devices used as CBPM delivery devices meet the requirements of the UK Medical Devices Regulations 2002 in the context of their use as CBPM delivery devices is a question the MHRA has the authority to investigate. This curriculum documents that the question exists.
The landscape as a whole
The regulatory landscape for CBPMs in the UK is extensive. The MHRA, the Home Office, NHS England, NICE, the CQC, and the UK Medical Devices Regulations 2002 together create a framework that governs almost every aspect of the CBPM pathway — from cultivation and manufacture to prescribing, dispensing, and clinical review.
The one aspect of the pathway that none of these bodies has addressed is the maintenance of the device through which the prescription is administered at home. That is not a minor gap. It is the gap between the prescription and the patient. It is where the clinical outcome is determined. And it has no regulatory standard.
This curriculum is the first attempt to create one. It is submitted to every relevant body as a contribution, not a complaint. The standard exists now. The question is whether the regulatory framework will adopt it.
In plain terms
Every part of your prescription is regulated. The medicine. The prescriber. The pharmacy. The clinic. The device — as a product. What happens to the device in your home is not regulated. No one has written the standard for it. Until now.
This curriculum is that standard. It has been submitted to the bodies that have the authority to make it official. Whether they do is their decision. That it exists is now a matter of public record.
Notice of Intent
This curriculum has been submitted to the MHRA, Home Office, NHS England, NICE, the Care Quality Commission, relevant parliamentary and clinical bodies, and device manufacturers operating within the UK prescribed CBPM pathway, as a formal educational contribution to a documented gap in patient care. It is published in perpetuity as a matter of public record. Purus Lumina reserves all rights to the curriculum structure, content, and methodology.
Get the Solution
The Purus Lumina Device Purification Solution — purpose-formulated for dry herb devices used in prescribed CBPM administration. 99.9% pharmaceutical-grade. UK-made. Available in 250ml, 500ml, and 1L.
Get the Device Purification Solution →
Continue to Module 18 – The Evidence Base →
← Back to Module 16 – The Home as a Clinical Environment
← Return to the Device Care Education hub
Module 17 is part of the Purus Lumina Device Care Curriculum — the world's first documented device care education programme for patients prescribed botanical medicine. Published as a matter of public record. Preserved in perpetuity.
This module was published on 4 July 2026 and exists in perpetuity as part of the Purus Lumina Device Care Curriculum — the world's first documented device care education programme for patients prescribed botanical medicine. It will not be removed.
Glenn Hailes · Director · Purus Lumina Ltd · 3rd Floor, 86–90 Paul Street · London EC2A 4NE · United Kingdom · Registered in England and Wales